DGAP: Developmental Genome Anatomy Project

DGAP:发育基因组解剖项目

基本信息

  • 批准号:
    6636462
  • 负责人:
  • 金额:
    $ 147.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-04-01 至 2006-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Applicant's Abstract): The goal of the Developmental Genome Anatomy Project (DGAP) is to identify genes critical in human development that are disrupted or dysregulated by balanced chromosomal rearrangements in humans with multiple congenital anomalies. Approximately 1 in 2000 newborns has an apparently balanced rearrangement, with a 6.1 percent risk for a serious congenital anomaly. These anomalies can include isolated defects ranging from cleft palate/lip, abdominal wall defects, limb defects, cardiac abnormalities or mental retardation, or they can occur as part of clinically recognizable syndromes. Of particular relevance is the fact that de novo structural abnormalities involving all chromosomes have been reported in association with congenital anomalies; it has been speculated that a significant number of such chromosomal breaks directly disrupt or dysregulate genes critical to specific molecular pathways. We propose to study individuals with multiple congenital anomalies and apparently balanced chromosomal rearrangements, with the aim of using balanced chromosomal rearrangements as signposts to identify these critical genes. The potential of DGAP will be greatly enhanced by rapidly evolving genomic resources including the complete human DNA sequence and an ordered FISH BAC map of the human genome. Collaborations established between cytogeneticists and clinical geneticists across the medical genetics community have been established to collect patient samples with a variety of developmental defects and balanced chromosomal rearrangements. Analysis of chromosomal breakpoints through FISH mapping studies will be used to identify single genomic clones containing relevant candidate sequences, and an online DGAP database is being created (Project 1). Molecular identification and analysis of candidate genes, as well as mutation studies in affected individuals will be the focus of subsequent studies (Project 2). Identification of expression patterns assessing tissue or temporal specificity will follow, as well as isolation of homologs in M. musculus and D. melanogaster (Project 3). Ultimately, transgenic animals will be used to study specific clones of interest to elucidate more fully their role in development (Project 3). DGAP constitutes a multi-laboratory and multi-institutional research endeavor which brings together the disciplines of clinical genetics, cytogenetics, molecular biology and developmental genetics to illuminate genes involved in fundamental pathways during human development.
说明书(申请人摘要):发展的目标 基因组解剖计划(DGAP)是为了识别人类关键基因 被平衡的染色体干扰或失调的发育 患有多种先天畸形的人类的重排。约1英寸 2000名新生儿有明显的平衡重排,风险为6.1% 因为严重的先天畸形。这些异常可能包括孤立的缺陷 从腭裂/唇裂,腹壁缺陷,肢体缺陷,心脏 异常或智力低下,或者它们可以作为临床的一部分发生 可辨认的综合症。特别相关的是,从头开始 涉及所有染色体的结构异常已在 与先天畸形有关;据推测, 大量这样的染色体断裂直接扰乱或失调 对特定分子途径至关重要的基因。我们建议研究个人 有多种先天畸形和明显的染色体平衡 重排,目的是使用平衡的染色体重排作为 识别这些关键基因的路标。DGAP的潜力将是 通过快速进化的基因组资源,包括完整的 人类DNA序列和人类基因组的有序鱼类BAC图谱。 细胞遗传学家和临床遗传学家之间建立的合作 已经建立了整个医学遗传学社区来收集患者 具有多种发育缺陷和染色体平衡的样本 重新安排。染色体断裂点的FISH定位分析 研究将用于鉴定包含相关基因的单个基因组克隆 正在创建一个在线DGAP数据库(项目1)。 候选基因的分子鉴定和分析,以及突变 对受影响个体的研究将是后续研究的重点。 (项目2)。鉴定评估组织或颞叶的表达模式 接下来将是特异性,以及分离肌肉分枝杆菌和D。 黑猩猩(项目3)。最终,转基因动物将被用于研究 感兴趣的特定克隆,以更充分地阐明它们在发育中的作用 (项目3)。DGAP构成了一个多实验室、多机构的 将临床遗传学学科结合在一起的研究努力, 细胞遗传学、分子生物学和发育遗传学阐明基因 参与人类发展的基本途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cynthia Casson Morton其他文献

Investigating the shared genetic architecture of uterine leiomyoma and breast cancer: A genome-wide cross-trait analysis
研究子宫肌瘤和乳腺癌的共同遗传结构:全基因组跨性状分析
  • DOI:
    10.1016/j.ajhg.2022.05.015
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Xueyao Wu;Chenghan Xiao;Zhitong Han;Li Zhang;Xunying Zhao;Yu Hao;Jinyu Xiao;C Scott Gallagher;Peter Kraft;Cynthia Casson Morton;Jiayuan Li;Xia Jiang
  • 通讯作者:
    Xia Jiang

Cynthia Casson Morton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cynthia Casson Morton', 18)}}的其他基金

Genetic Approach to Therapy for DFNA9
DFNA9 的基因治疗方法
  • 批准号:
    10681990
  • 财政年份:
    2023
  • 资助金额:
    $ 147.78万
  • 项目类别:
SEQuencing a Baby for an Optimal Outcome (SEQaBOO)
对婴儿进行测序以获得最佳结果 (SEQaBOO)
  • 批准号:
    9021176
  • 财政年份:
    2016
  • 资助金额:
    $ 147.78万
  • 项目类别:
Genetic Studies of Uterine Leiomyomata
子宫平滑肌瘤的遗传学研究
  • 批准号:
    7848517
  • 财政年份:
    2010
  • 资助金额:
    $ 147.78万
  • 项目类别:
Genetic Studies of Uterine Leiomyomata
子宫平滑肌瘤的遗传学研究
  • 批准号:
    8300035
  • 财政年份:
    2010
  • 资助金额:
    $ 147.78万
  • 项目类别:
Genetic Studies of Uterine Leiomyomata
子宫平滑肌瘤的遗传学研究
  • 批准号:
    8637095
  • 财政年份:
    2010
  • 资助金额:
    $ 147.78万
  • 项目类别:
Genetic Studies of Uterine Leiomyomata
子宫平滑肌瘤的遗传学研究
  • 批准号:
    8116076
  • 财政年份:
    2010
  • 资助金额:
    $ 147.78万
  • 项目类别:
Finding Genes for Uterine Fibroids
寻找子宫肌瘤的基因
  • 批准号:
    7114920
  • 财政年份:
    2003
  • 资助金额:
    $ 147.78万
  • 项目类别:
Finding Genes for Uterine Fibroids
寻找子宫肌瘤的基因
  • 批准号:
    7271865
  • 财政年份:
    2003
  • 资助金额:
    $ 147.78万
  • 项目类别:
Finding Genes for Uterine Fibroids
寻找子宫肌瘤的基因
  • 批准号:
    6740757
  • 财政年份:
    2003
  • 资助金额:
    $ 147.78万
  • 项目类别:
Finding Genes for Uterine Fibroids
寻找子宫肌瘤的基因
  • 批准号:
    6805750
  • 财政年份:
    2003
  • 资助金额:
    $ 147.78万
  • 项目类别:

相似海外基金

The pathogenesis of ALG14-congenital disorders of glycosylation.
ALG14-先天性糖基化障碍的发病机制。
  • 批准号:
    23K14967
  • 财政年份:
    2023
  • 资助金额:
    $ 147.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identifying New Therapeutics and Molecular Mechanisms in Congenital Disorders of Glycosylation.
确定先天性糖基化疾病的新疗法和分子机制。
  • 批准号:
    10644811
  • 财政年份:
    2023
  • 资助金额:
    $ 147.78万
  • 项目类别:
Investigating the Genotype-Phenotype Relationships that Underlie Congenital Disorders with Cardiovascular Symptoms through Population-scale Analyses
通过人群规模分析研究具有心血管症状的先天性疾病背后的基因型-表型关系
  • 批准号:
    10724185
  • 财政年份:
    2023
  • 资助金额:
    $ 147.78万
  • 项目类别:
Identifying understudied protein-related glycoproteome disruption in Congenital Disorders of Glycosylation
识别先天性糖基化障碍中尚未研究的蛋白质相关糖蛋白组破坏
  • 批准号:
    10725869
  • 财政年份:
    2023
  • 资助金额:
    $ 147.78万
  • 项目类别:
Pathogenic Mechanisms of Congenital Disorders of Glycosylation
先天性糖基化障碍的发病机制
  • 批准号:
    10633548
  • 财政年份:
    2023
  • 资助金额:
    $ 147.78万
  • 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
  • 批准号:
    10480649
  • 财政年份:
    2022
  • 资助金额:
    $ 147.78万
  • 项目类别:
Assessment of a potential application of endogenous stem cells to treat congenital disorders
评估内源干细胞治疗先天性疾病的潜在应用
  • 批准号:
    22K20740
  • 财政年份:
    2022
  • 资助金额:
    $ 147.78万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
  • 批准号:
    10616658
  • 财政年份:
    2022
  • 资助金额:
    $ 147.78万
  • 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
  • 批准号:
    10040788
  • 财政年份:
    2020
  • 资助金额:
    $ 147.78万
  • 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
  • 批准号:
    10250486
  • 财政年份:
    2020
  • 资助金额:
    $ 147.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了